- Pharmaceutical giant AstraZeneca said a late-stage trial its dual immunotherapy regimen live cancer drug had met its primary goal.

The trial met its primary endpoint of overall survival with a single dose of tremelimumab plus Imfinzi every four weeks versus sorafenib.

Results from the a phase 3 trial showed a single dose of tremelimumab, an antibody, and Imfinzi, demonstrated a statistically significant and clinically meaningful overall survival benefit versus sorafenib as a treatment for patients with hepatocellular carcinoma, a type of liver cancer.

Imfinzi alone demonstrated non-inferior overall survival to sorafenib with a numerical trend in favour of Imfinzi and an improved tolerability profile compared to sorafenib.

Story provided by